), the company believes it fully complied with the disclosure policy at issue, and had no undisclosed patents or applications during the relevant time period.
Jabil Circuit (JBL
) posted $0.12 vs. $0.16 Q3 cash EPS on 18% revenue decline and sees $0.14-$0.16 Q4 cash EPS on sales of $920M-$960M. S&P cuts estimates. JP Morgan added the stock to its Focus List.
Morgan Stanley (MWD
) posted $0.72 vs. $0.82 Q2 EPS on 17% lower revenue.
) posted $1.51 vs. $1.40 Q2 EPS on a 13% revenue rise and sees fiscal 2002 EPS of $6.50; at the high end of its previous goal. Lennar also raised its fiscal 2003 EPS guidance to $7.50- $8.00.
) reportedly sees better than expected Q2 and fiscal 2003 results.
) plans to wind down its Intel Online Services Web hosting business and record a $100M Q2 charge.
) sees $0.08-$0.10 Q3 EPS on lower than expected revenues of $1.4B-$1.45B. S&P maintains hold. Merrill downgraded to long term neutral from buy.
) posted better than expected $0.14 vs. $0.15 Q4 EPS from operations on 15% lower revenues. CS Boston, Lehman reiterates buy. Morgan Stanley maintains overweight. CIBC World keeps hold.
Advanced Micro (AMD
) expects a substantial Q2 operating loss on sales of $620M-$700M, vs. the previous estimate for sales of $820M- $900M. S&P downgraded to avoid; UBS Warburg reportedly downgraded to hold.
Micron Technologies (MU
) confirmed that the Antitrust Division of the Justice Dept. is conducting an industry-wide investigation into alleged anticompetitive practices among DRAM makers; it has received a grand jury subpoena seeking information relating to the government's investigation.
) says Q3 revenue, including the purchase of ONI Systems, could be down meaningfully from its stand alone Q2. Ciena says it will eliminate 335 employees. S&P reiterates sell.
) sees a $0.03 loss to $0.02 EPS for Q2, citing rapid increases in basic raw material and recovered fiber.
Oak Technology (OAKT
) sees a $0.05-$0.09 Q4 loss (pro forma), including inventory reserves, but excluding charges and expenses; the company expects revenues to decline sequentially rather than the previous outlook of up slightly.
) expects Q2 EPS to be within middle of $0.43-$0.49 range; it reaffirmed the $1.60-$1.67 2002 EPS outlook. Pulitzer also expects newsprint prices to increase 15% or more over the rest of the year.
According to a press report, Congressional investigators are examining why a Merrill Lynch (MER
) biotech analyst said on Dec 27-- the day before ImClone's Erbitux drug was rejected -- that there was "speculation" that the FDA might refuse ImClone's application.